147 related articles for article (PubMed ID: 25004973)
1. Structural basis of the transactivation deficiency of the human PPARγ F360L mutant associated with familial partial lipodystrophy.
Lori C; Pasquo A; Montanari R; Capelli D; Consalvi V; Chiaraluce R; Cervoni L; Loiodice F; Laghezza A; Aschi M; Giorgi A; Pochetti G
Acta Crystallogr D Biol Crystallogr; 2014 Jul; 70(Pt 7):1965-76. PubMed ID: 25004973
[TBL] [Abstract][Full Text] [Related]
2. New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.
Lüdtke A; Buettner J; Schmidt HH; Worman HJ
J Med Genet; 2007 Sep; 44(9):e88. PubMed ID: 17766367
[TBL] [Abstract][Full Text] [Related]
3. Impaired peroxisome proliferator-activated receptor gamma function through mutation of a conserved salt bridge (R425C) in familial partial lipodystrophy.
Jeninga EH; van Beekum O; van Dijk AD; Hamers N; Hendriks-Stegeman BI; Bonvin AM; Berger R; Kalkhoven E
Mol Endocrinol; 2007 May; 21(5):1049-65. PubMed ID: 17312272
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor-gamma C190S mutation causes partial lipodystrophy.
Lüdtke A; Buettner J; Wu W; Muchir A; Schroeter A; Zinn-Justin S; Spuler S; Schmidt HH; Worman HJ
J Clin Endocrinol Metab; 2007 Jun; 92(6):2248-55. PubMed ID: 17356052
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor-γ mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system.
Auclair M; Vigouroux C; Boccara F; Capel E; Vigeral C; Guerci B; Lascols O; Capeau J; Caron-Debarle M
Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):829-38. PubMed ID: 23393388
[TBL] [Abstract][Full Text] [Related]
6. Lessons from human mutations in PPARgamma.
Hegele RA
Int J Obes (Lond); 2005 Mar; 29 Suppl 1():S31-5. PubMed ID: 15711581
[TBL] [Abstract][Full Text] [Related]
7. Natural helix 9 mutants of PPARγ differently affect its transcriptional activity.
Broekema MF; Massink MPG; Donato C; de Ligt J; Schaarschmidt J; Borgman A; Schooneman MG; Melchers D; Gerding MN; Houtman R; Bonvin AMJJ; Majithia AR; Monajemi H; van Haaften GW; Soeters MR; Kalkhoven E
Mol Metab; 2019 Feb; 20():115-127. PubMed ID: 30595551
[TBL] [Abstract][Full Text] [Related]
8. Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma.
Monajemi H; Zhang L; Li G; Jeninga EH; Cao H; Maas M; Brouwer CB; Kalkhoven E; Stroes E; Hegele RA; Leff T
J Clin Endocrinol Metab; 2007 May; 92(5):1606-12. PubMed ID: 17299075
[TBL] [Abstract][Full Text] [Related]
9. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
Waku T; Shiraki T; Oyama T; Fujimoto Y; Maebara K; Kamiya N; Jingami H; Morikawa K
J Mol Biol; 2009 Jan; 385(1):188-99. PubMed ID: 18977231
[TBL] [Abstract][Full Text] [Related]
10. The conserved residue Phe273(282) of PPARalpha(gamma), beyond the ligand-binding site, functions in binding affinity through solvation effect.
Yue L; Ye F; Xu X; Shen J; Chen K; Shen X; Jiang H
Biochimie; 2005 Jun; 87(6):539-50. PubMed ID: 15935279
[TBL] [Abstract][Full Text] [Related]
11. Insights into the mechanism of partial agonism: crystal structures of the peroxisome proliferator-activated receptor gamma ligand-binding domain in the complex with two enantiomeric ligands.
Pochetti G; Godio C; Mitro N; Caruso D; Galmozzi A; Scurati S; Loiodice F; Fracchiolla G; Tortorella P; Laghezza A; Lavecchia A; Novellino E; Mazza F; Crestani M
J Biol Chem; 2007 Jun; 282(23):17314-24. PubMed ID: 17403688
[TBL] [Abstract][Full Text] [Related]
12. Mode of peroxisome proliferator-activated receptor γ activation by luteolin.
Puhl AC; Bernardes A; Silveira RL; Yuan J; Campos JL; Saidemberg DM; Palma MS; Cvoro A; Ayers SD; Webb P; Reinach PS; Skaf MS; Polikarpov I
Mol Pharmacol; 2012 Jun; 81(6):788-99. PubMed ID: 22391103
[TBL] [Abstract][Full Text] [Related]
13. Vascular placental abnormalities and newborn death in a pregnant diabetic woman with familial partial lipodystrophy type 3: a possible role for peroxisome proliferator-activated receptor γ.
Castell AL; Hiéronimus S; Lascols O; Fournier T; Fénichel P
Diabetes Metab; 2012 Oct; 38(4):367-9. PubMed ID: 22559930
[TBL] [Abstract][Full Text] [Related]
14. Novel peroxisome proliferator-activated receptor gamma mutation in a family with familial partial lipodystrophy type 3.
Miehle K; Porrmann J; Mitter D; Stumvoll M; Glaser C; Fasshauer M; Hoffmann K
Clin Endocrinol (Oxf); 2016 Jan; 84(1):141-8. PubMed ID: 26119484
[TBL] [Abstract][Full Text] [Related]
15. Single-Nucleotide Polymorphism of PPARγ, a Protein at the Crossroads of Physiological and Pathological Processes.
Petrosino M; Lori L; Pasquo A; Lori C; Consalvi V; Minicozzi V; Morante S; Laghezza A; Giorgi A; Capelli D; Chiaraluce R
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208577
[TBL] [Abstract][Full Text] [Related]
16. A Pharmacogenetic Approach to the Treatment of Patients With
Agostini M; Schoenmakers E; Beig J; Fairall L; Szatmari I; Rajanayagam O; Muskett FW; Adams C; Marais AD; O'Rahilly S; Semple RK; Nagy L; Majithia AR; Schwabe JWR; Blom DJ; Murphy R; Chatterjee K; Savage DB
Diabetes; 2018 Jun; 67(6):1086-1092. PubMed ID: 29622583
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for PPARγ transactivation by endocrine-disrupting organotin compounds.
Harada S; Hiromori Y; Nakamura S; Kawahara K; Fukakusa S; Maruno T; Noda M; Uchiyama S; Fukui K; Nishikawa J; Nagase H; Kobayashi Y; Yoshida T; Ohkubo T; Nakanishi T
Sci Rep; 2015 Feb; 5():8520. PubMed ID: 25687586
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for differential activities of enantiomeric PPARγ agonists: Binding of S35 to the alternate site.
Jang JY; Koh M; Bae H; An DR; Im HN; Kim HS; Yoon JY; Yoon HJ; Han BW; Park SB; Suh SW
Biochim Biophys Acta Proteins Proteom; 2017 Jun; 1865(6):674-681. PubMed ID: 28342850
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
Montanari R; Saccoccia F; Scotti E; Crestani M; Godio C; Gilardi F; Loiodice F; Fracchiolla G; Laghezza A; Tortorella P; Lavecchia A; Novellino E; Mazza F; Aschi M; Pochetti G
J Med Chem; 2008 Dec; 51(24):7768-76. PubMed ID: 19053776
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of non-obese diabetic patients with marked insulin resistance identifies a novel familial partial lipodystrophy-associated PPARγ mutation (Y151C).
Visser ME; Kropman E; Kranendonk ME; Koppen A; Hamers N; Stroes ES; Kalkhoven E; Monajemi H
Diabetologia; 2011 Jul; 54(7):1639-44. PubMed ID: 21479595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]